Galectin Therapeutics Inc. (NASDAQ: GALT) Stock Information | RedChip

Galectin Therapeutics Inc. (NASDAQ: GALT) Listen to this Section


$2.17
-0.0850 ( -3.78% ) 27.3K

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Market Data


Open


$2.17

Previous close


$2.25

Volume


27.3K

Market cap


$138.59M

Day range


$2.13 - $2.28

52 week range


$1.47 - $4.27

Insider Ownership Transactions

Total Amount Purchased: -33,999.00 | $ -73,607.84

Date Type Amount Purchased Purchaser
2023-09-18 Sale -10947.00 LEWIS JOEL
2023-09-01 Sale -11010.00 LEWIS JOEL
2023-08-15 Sale -12042.00 LEWIS JOEL

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Jan 16, 2024
4 Insider transactions 1 Jan 02, 2024
4 Insider transactions 1 Dec 18, 2023
8-k 8K-related 12 Dec 11, 2023
8-k 8K-related 13 Dec 07, 2023
4 Insider transactions 1 Dec 01, 2023
5 Other 1 Dec 01, 2023
4 Insider transactions 1 Nov 15, 2023

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.